Altered galectin-1 serum levels in patients diagnosed with high-grade glioma. - Wikidata - awgldk - TriplyDB

Altered galectin-1 serum levels in patients diagnosed with high-grade glioma.

Altered galectin-1 serum levels in patients diagnosed with high-grade glioma.

http://www.wikidata.org/entity/Q50860307

about

Circulating glioma biomarkers Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients.Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course.Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma.Galectins and neovascularization in central nervous system tumors.Brain Tumor Immunotherapy: What have We Learned so Far?Clinical-Grade Human Multipotent Adult Progenitor Cells Block CD8+ Cytotoxic T Lymphocytes.Role of Galectins in Multiple Myeloma.Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy.Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives.Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke.Serum galectin-3, but not galectin-1, levels are elevated in schizophrenia: implications for the role of inflammation.Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC.Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008.Endogenous Galectin-1 in T Lymphocytes Regulates Anti-prostate Cancer Immunity Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker

P2860

Q26830329-F33D1D71-98A1-4F34-914E-042E436F8DE8 Q33683101-11E0D62C-B50C-41A5-99AA-8D08279B6145 Q35955393-8AEA59FA-B5FA-4754-87F0-C79678336B76 Q36821077-E54A78E4-AC9C-416A-9275-CF0A7FA77E28 Q38174863-6F772153-0CF0-41B1-B254-D3817C169F72 Q38214808-CA0B5847-1A8A-41E1-8E19-A27A0854E0F5 Q38542113-5AE27F27-1E7A-4437-BED1-265B6FB916B7 Q38837177-176C5A12-5D38-4721-AA37-36034E64DEF6 Q47282400-6E10D5CC-845B-4EAA-979C-C530AEA6C0C7 Q47706727-ACC52E96-10D8-471E-8983-E19209D65F38 Q48270428-2426B5C0-74DE-4132-A549-58DF8BB1C92C Q49206188-ADB3B27A-909B-4E86-9DA7-64A8A21006E0 Q50895945-464E8E35-B0AE-4346-A080-BA66D4104DC8 Q51526266-BEA1BDA1-B40E-4346-AFC5-86AF97F5AADF Q52724033-1D2564B7-92E7-4CBD-81CE-B57E0CEA0587 Q57491420-545CF461-51F3-4547-9F3D-04DA9118B23B Q58779449-0AFA8BF8-38F8-41FA-9BC9-23D8E152C956

P2860

Altered galectin-1 serum levels in patients diagnosed with high-grade glioma.

http://www.wikidata.org/entity/Q50860307

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Altered galectin-1 serum levels in patients diagnosed with high-grade glioma.

@en

Altered galectin-1 serum levels in patients diagnosed with high-grade glioma.

@nl

type

label

Altered galectin-1 serum levels in patients diagnosed with high-grade glioma.

@en

Altered galectin-1 serum levels in patients diagnosed with high-grade glioma.

@nl

prefLabel

Altered galectin-1 serum levels in patients diagnosed with high-grade glioma.

@en

Altered galectin-1 serum levels in patients diagnosed with high-grade glioma.

@nl

P1433

Q50860307-BD4595F2-FD71-47DA-99CD-20FFC729510B

P1476

Q50860307-D03A8299-4FD7-466C-AE47-B48136A8401E

P2093

Q50860307-10518200-C560-4D35-85ED-34CA2337AE7D

Q50860307-15B3898F-8180-4197-8F45-2567A1C2600B

Q50860307-4CD893C7-E8BD-4664-B173-89D1B7CA0A05

Q50860307-6C0B247A-B62D-40CC-8872-CAFC57DD5EF3

Q50860307-9F2F7A4D-0691-40E9-B7A0-B96E987504A7

Q50860307-BB6C363B-9B01-45D3-9613-512E9CF9FC6C

Q50860307-C1438C92-EE4C-4D52-B04F-C0972E7AF8D3

P2860

Q50860307-02A7998F-83DE-412E-BF33-F856C8404F61

Q50860307-09423C31-17C0-4CB9-8FC3-9A06D6321C3E

Q50860307-1BDB5E90-AAC1-4607-9963-F37101E092B8

Q50860307-2889C607-6B70-4194-9614-1917FCE704A3

Q50860307-4F0B292C-E2FC-4E51-9E17-3581A7CE4E13

Q50860307-541F7C93-E0E0-4E2C-8D3B-43EC9FADCA57

Q50860307-678FA3AA-A07E-49CF-B994-444267B92406

Q50860307-6C9BEB1B-9FBC-4BE3-B4EA-B6AC42AF8F2F

Q50860307-73318621-2731-494E-82DB-39429BA4F343

Q50860307-7BF44594-9390-4B0B-9249-5103F5575ABF

P2888

Q50860307-3307E008-05B5-4A5C-9A70-EC301FB65ED6

P304

Q50860307-42DCA432-D272-415F-ABFA-F31AEA902171

P31

Q50860307-E9D65E72-C7CB-46A1-BD4A-5C42DE371845

P356

Q50860307-438E11FA-3FEE-4E0D-9CDE-BA2B966DC8E2

P433

Q50860307-A4D84DA1-9204-4D55-8CC3-3F37753B70E2

P478

Q50860307-400946A3-8F1B-44B9-925C-3B382FD56370

P50

Q50860307-D654DA4D-5C86-4050-AAF4-132B65D6B4A6

P577

Q50860307-EA1291EB-1F34-4BA3-851C-DC40C5EB3C1D

P698

Q50860307-523478DA-2190-44B6-9BE9-150B3C8BBBF8

P356

S11060-013-1201-8

P1433

Journal of Neuro-Oncology

P1476

Altered galectin-1 serum levels in patients diagnosed with high-grade glioma.

@en

P2093

Florence Lefranc

http://www.w3.org/2001/XMLSchema#string

Matthias Van Woensel

http://www.w3.org/2001/XMLSchema#string

Robert Kiss

http://www.w3.org/2001/XMLSchema#string

Stefaan W Van Gool

http://www.w3.org/2001/XMLSchema#string

Steffen Fieuws

http://www.w3.org/2001/XMLSchema#string

Tina Verschuere

http://www.w3.org/2001/XMLSchema#string

Veronique Mathieu

http://www.w3.org/2001/XMLSchema#string

P2860

The 2007 WHO classification of tumours of the central nervous system

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Galectins and gliomas.

Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma.

Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion.

Cost of migration: invasion of malignant gliomas and implications for treatment.

Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy

Genetic pathways to primary and secondary glioblastoma

Structural features for α-galactomannan binding to galectin-1.

Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma.

P2888

s11060-013-1201-8

P304

9-17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11060-013-1201-8

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

Steven De Vleeschouwer

P577

2013-07-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23824536

http://www.w3.org/2001/XMLSchema#string